<DOC>
	<DOCNO>NCT01966822</DOCNO>
	<brief_summary>Protease inhibitor ( PI ) associate acceleration bone mineral density loss HIV-infected individual enhance osteoclast activity , although controversial data also publish . A first study suggest increase bone mineral density switch PI raltegravir , first generation integrase inhibitor , data subject . Based data PI decrease bone mineral density accelerate osteoclast cell discontinuation drug could improve bone mineralization , propose randomize prospective multicenter study assess impact switch PI dolutegravir bone mineral density patient low bone mineral density receive PI-containing regimen . At time , study help assess antiviral efficacy safety PI-sparing regimen include dolutegravir simplification strategy virologically suppress patient .</brief_summary>
	<brief_title>Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density</brief_title>
	<detailed_description>The second generation integrase inhibitor dolutegravir demonstrate good virological immunological outcome antiretroviral-naive subject , compare efavirenz , ( SPRING 1 study ) . As well , active HIV strain resistant first-generation inhibitor raltegravir elvitegravir heavily treatment-experienced patient ( VIKING study ) . Additionally , safe well tolerate two year use . It administer daily need boost , food requirement long half-life . The easy posology pharmacokinetics , together antiviral potency , make drug good alternative simplification approach . However , clinical data available support switch protease inhibitor nucleoside reverse transcriptase inhibitor dolutegravir virologically suppress HIV-treated subject . Protease inhibitor ( PI ) associate acceleration bone mineral density loss HIV-infected individual enhance osteoclast activity , although controversial data also publish . A first study suggest increase bone mineral density switch PI raltegravir , first generation integrase inhibitor , data subject . Based data PI decrease bone mineral density accelerate osteoclast cell discontinuation drug could improve bone mineralization , propose randomize prospective multicenter study assess impact switch PI dolutegravir bone mineral density patient low bone mineral density receive PI-containing regimen . At time , study help assess antiviral efficacy safety PI-sparing regimen include dolutegravir simplification strategy virologically suppress patient .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>1 . HIVinfected patient 18 year . 2 . In current antiretroviral therapy abacavir lamivudine ( Kivexa ) plus ritonavirboosted PI , least 6 month . 3 . Viral suppression ( HIV RNA &lt; 50 copy / ml ) least 12 month . 4 . Tscore ≤ 1 evaluate DEXA ( do last 6 month ) . 5 . Signed informed consent . 6 . In potential childbearing woman , commitment use barrier contraceptive method throughout study . 1 . Suspected documented resistance integrase inhibitor reverse transcriptase inhibitor , nucleoside analogue . 2 . Osteoporosis / osteopenia secondary ( testosterone deficiency , thyroid disease ... ) , except vitamin D deficiency 3 . Treatment bisphosphonates last 6 month . 4 . Have use integrase inhibitor 5 . Pregnant breastfeeding . 6 . Patients alanine aminotransferase ( ALT ) &gt; 5 time upper limit normal ( ULN ) ALT ≥ 3 time ULN bilirubin ≥ 1.5 time ULN ( direct bilirubin &gt; 35 % ) 7 . Patients severe hepatic dysfunction ( Class B C ) accord ChildPugh classification 8 . Patients infect hepatitis B virus ( HBV ) use entecavir telbivudine . 9 . Patients infected hepatitis C virus ( HCV ) expect begin treatment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone mineral density</keyword>
	<keyword>Dual-energy X-ray absorptiometry</keyword>
	<keyword>HIV infection</keyword>
	<keyword>Dolutegravir</keyword>
	<keyword>Integrase inhibitor</keyword>
</DOC>